Cycrimine
Identification
- Name
- Cycrimine
- Accession Number
- DB00942
- Description
Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Cycrimine (DB00942)
- Weight
- Average: 287.4397
Monoisotopic: 287.224914555 - Chemical Formula
- C19H29NO
- Synonyms
- (±)-cycrimine
- alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol
- Cicrimina
- Cycrimine
- Cycriminum
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
For treatment and management of Parkinson's disease.
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Cycrimine is a central anticholenergic used in the treatment of the symptoms of Parkinson's disease. It is a drug used to reduce levels of acetylcholine. Acetylcholine is usually in balance with dopamine neurotransmitters, however lower levels of dopamine are present in the brain of patients suffering from Parkinson's disease. By lowering levels of acetylcholine, it is thought that this balance may be restored.
- Mechanism of action
Cycrimine binds the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of Parkinson's disease.
Target Actions Organism AMuscarinic acetylcholine receptor M1 antagonistHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
14-21%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. Aclidinium The risk or severity of adverse effects can be increased when Cycrimine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Cycrimine. Agomelatine Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Cycrimine. Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Cycrimine. Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. Alosetron Alosetron may increase the central nervous system depressant (CNS depressant) activities of Cycrimine. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Cycrimine hydrochloride 9RB4L4K895 126-02-3 WBCWFMFZMRFRLT-UHFFFAOYSA-N - International/Other Brands
- Pagitane (Lilly)
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Aralkylamines
- Alternative Parents
- Piperidines / Benzene and substituted derivatives / Tertiary alcohols / 1,3-aminoalcohols / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
- Substituents
- 1,3-aminoalcohol / Alcohol / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Hydrocarbon derivative / Monocyclic benzene moiety / Organic oxygen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- piperidines, tertiary alcohol, tertiary amino compound (CHEBI:59692)
Chemical Identifiers
- UNII
- 543567RFQQ
- CAS number
- 77-39-4
- InChI Key
- SWRUZBWLEWHWRI-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H29NO/c21-19(18-11-5-6-12-18,17-9-3-1-4-10-17)13-16-20-14-7-2-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2
- IUPAC Name
- 1-cyclopentyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol
- SMILES
- OC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1
References
- Synthesis Reference
Ruddy, A.W. and Becker, T.J.; U.S. Patent 2,680,115; June 1, 1954; assigned to Winthrop-Stearns Inc.
- General References
- Vedasiromoni JR, Ganguly DK: Cycrimine on rat diaphragm. Arch Int Pharmacodyn Ther. 1976 Jan;219(1):64-9. [PubMed:1267542]
- External Links
- Human Metabolome Database
- HMDB0015077
- PubChem Compound
- 2911
- PubChem Substance
- 46506736
- ChemSpider
- 2808
- 22037
- ChEBI
- 59692
- ChEMBL
- CHEMBL1201227
- Therapeutic Targets Database
- DAP001120
- PharmGKB
- PA164749387
- Wikipedia
- Cycrimine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Eli lilly and co
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 112-113 Ruddy, A.W. and Becker, T.J.; U.S. Patent 2,680,115; June 1, 1954; assigned to Winthrop-Stearns Inc. logP 4 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00909 mg/mL ALOGPS logP 4.15 ALOGPS logP 3.79 ChemAxon logS -4.5 ALOGPS pKa (Strongest Acidic) 13.84 ChemAxon pKa (Strongest Basic) 9.32 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 23.47 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 88.6 m3·mol-1 ChemAxon Polarizability 34.78 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9465 Blood Brain Barrier + 0.9686 Caco-2 permeable + 0.6502 P-glycoprotein substrate Substrate 0.654 P-glycoprotein inhibitor I Inhibitor 0.5407 P-glycoprotein inhibitor II Non-inhibitor 0.8279 Renal organic cation transporter Inhibitor 0.7739 CYP450 2C9 substrate Non-substrate 0.8273 CYP450 2D6 substrate Non-substrate 0.8337 CYP450 3A4 substrate Non-substrate 0.5554 CYP450 1A2 substrate Non-inhibitor 0.9193 CYP450 2C9 inhibitor Non-inhibitor 0.9181 CYP450 2D6 inhibitor Inhibitor 0.9056 CYP450 2C19 inhibitor Non-inhibitor 0.9102 CYP450 3A4 inhibitor Non-inhibitor 0.8257 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9336 Ames test Non AMES toxic 0.856 Carcinogenicity Non-carcinogens 0.9292 Biodegradation Not ready biodegradable 0.9172 Rat acute toxicity 2.7260 LD50, mol/kg Not applicable hERG inhibition (predictor I) Strong inhibitor 0.6253 hERG inhibition (predictor II) Inhibitor 0.5169
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-0002-9000000000-43de7e4a24aa5556ad34 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Vedasiromoni JR, Ganguly DK: Cycrimine on rat diaphragm. Arch Int Pharmacodyn Ther. 1976 Jan;219(1):64-9. [PubMed:1267542]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 13:24 / Updated on April 03, 2021 09:41